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ABSTRACT 
The triplatinum complex of the 2,4,6-Tris(2-pyrimidyl)-1,3,5-triazine ligand, Pt3TPymT 
hereafter, has been prepared and characterized for the first time. NMR studies point out 
that the three platinum(II) centers possess an identical coordination environment. The 
interactions of Pt3TPymT with DNA were explored in comparison to the free ligand. 
Specifically, fluorescence, mass spectrometry, viscometry and melting measurements 
were carried out.  In contrast to expectations, the obtained data reveal that no 
intercalative binding takes place; we propose that binding of Pt3TPymT to DNA mainly 
occurs through external/groove binding.  
 
 
1. INTRODUCTION 
The 2,4,6-Tris(2-pyrimidyl)-1,3,5-triazine ligand (TPymT) has been known for more 
than 60 years [1] and still appears to be very attractive for its peculiar coordination 
chemistry properties. Indeed, this ligand has the potential to bind tightly three metal ions 
at three identical sites through a N3 donor set (Figure 1). However, only a limited number 
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of studies utilizing this ligand have appeared so far owing to its general unavailability, 
poor solubility in common solvents, and to the facile hydrolysis of the central triazine 
fragment; among these, the complexes of TPymT with Pb2+, Tl+ and UO22+ were obtained 
and characterized by Lippard and co-workers several years ago [2]. The state of art of the 
coordination chemistry studies centred on this ligand has been recently recapitulated by 
Murugesu and coworkers [3]. In this frame, of particular interest are the recent results 
concerning the trisilver complex of TPymT, Ag3TPymT, that was prepared and 
characterized by Murugesu et al [4]; notably, high resolution crystallographic results 
revealed the presence of an extended planar system.  
 
We noticed that the platinum(II) complex of the TPymT ligand has not been reported and 
described so far, either in solution or in the solid state. We argued that this complex might 
be prepared and characterized quite straightforwardly in analogy to the case of the 
trisilver complex. In principle, the triplatinum complex of the TPymT ligand should 
exhibit a widely extended planar structure together with a highly cationic character and 
thus behave as an efficient intercalating agent for double helix DNA. If this is proved, this 
complex might be a good candidate for medicinal chemistry studies as a potential 
anticancer drug.  
It is worthy reminding that platinum(II) complexes of thio-pyridyl-triazine are 
potential antitumor agents, with a cytotoxic activity greater than cisplatin and the free 
ligand [5]. Notably, ruthenium(II) diamino-triazine aquo-complexes were shown to 
strongly interact with DNA [6]. However, as for the possible use of this family of 
complexes as antitumor agents, to be best of our knowledge, only a Ru(II) complex 
has been tested [7]. In view of these arguments, we report here the synthesis and detailed 
chemical characterization of the triplatinum complex of TPymT and explore its 
interactions with various DNA molecules. 
 
< Figure 1 near here> 
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2. MATERIALS AND METHODS 
 
2.1 Double and single stranded DNA   
Appropriate amounts of the ligand tris-2,4,6-(2-pyrimidyl)-1,3,5-triazine (TPymT, L) or 
of its platinum complex ([(TPymT)Pt3(Cl)3]3+, Pt3L3+) were accurately weighted out and 
dissolved in the buffer or in dimethyl sulfoxide (DMSO), respectively. The stock 
solutions so obtained were ca. 10-3 M. The buffer is an aqueous solution of 0.1 M NaCl 
and 0.01 NaCac (sodium cacodylate) at pH 7.0. The water used always comes from an 
ultra-pure grade purification system (AriumPro, Sartorius). The molar concentration of 
either ligand or complex (i.e. dye, drug) will be indicated as CD. 
DNA was from calf thymus, and in particular a double helix B-form, highly polymerised 
salt from Sigma. It was sonicated to reduce its length to ca. 500 base pairs following a 
known procedure [8]. The molar concentration (in base pairs) of the DNA solutions, 
CDNA, was spectrophotometrically evaluated (ε = 13200 M-1 cm-1 at λ = 260 nm, [NaCl] = 
0.1 M, [NaCac] = 0.01 M, pH 7.0 [9]) The solutions of ethidium bromide solution (EB, 
purity > 99%, Sigma) were obtained by dissolving the appropriate amount of the solid in 
the buffer; their molar concentration (CEB) was evaluated spectrophotometrically (ε = 
5600 M-1 cm-1 at λ = 480 nm, [NaCl] = 0.1 M, [NaCac] = 0.01 M [10]). 
The dodecameric oligonucleotide CTACGGTTTCAC (ODN) was purchased from 
Sigma-Aldrich and used without further purification and its ultra-pure water 10-3 M stock 
solution was stored at -20 °C. Solutions of ODN (10-5 M in ultra-pure water) were 
incubated for 72 h at 37° C at different complex:ODN ratios, i.e. 0.2:1 and 0.5:1 in the 
presence of 1% dimethylformamide (DMF). 
 
2.2 Spectrophotometric analysis   
Spectrophotometric measurements/titrations were done in triplicates on a double beam 
Shimadzu 2450 apparatus. Light emission measurements were done using a Perkin Elmer 
LS55 instrument. Both spectrophotometer and spectrofluorometer are thermostatted by a 
water bath (± 0.1 °C). The actual temperature inside the cell compartment was controlled 
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by a mini-thermometer. Any addition during spectroscopic titrations was done directly 
into the cell by means of a glass syringe connected to a micrometric screw (Mitutoyo, 
additions as small as 0.164 µL possible with high accuracy). In the case of the DNA 
melting experiments, care was taken to increase the temperature very slowly, so to ensure 
system stabilization before data reading (5°C/15’ + 30’ equilibration).  
 
2.3 Viscosimetry 
Viscosimetric experiments were carried out using a semi-micro Ubbelohde capillary (1.0 
mL volume), immersed in a temperature-controlled water bath (± 0.1° C). Flow times 
were measured by a stop watch at least in quintuplicates.  
 
2.4 Mass spectrometry 
The electrospray mass spectrometric study (ESI-MS) of the oligonucleotide (ODN)-
Pt3L3+ mixture was performed by direct infusion at 10 µl min−1 flow rate in an 
TripleTOF® 5600+ System mass spectrometer (Sciex, Framingham, MA, U.S.A.), 
equipped with a TurboIonSpray® interface operating with an ESI probe. The MS source 
parameters were optimized and were as follows: negative polarity, Ionspray Voltage 
Floating (ISVF) -4500 V, Temperature (TEM) 400° C, Ion source Gas 1 (GS1) 40; Ion 
source Gas 2 (GS2) 30; Curtain Gas (CUR) 25, Declustering Potential (DP) -50 V, 
Collision Energy (CE) -10 V. For acquisition, Analyst TF software 1.7.1 (Sciex) was 
used and deconvoluted spectra were obtained by using the Bio Tool Kit version 2.2 tool 
for Peakview 2.2 software (Sciex). The mass spectrometer was operated with a resolving 
power greater than 30 000fwhm for TOF MS scans. 
 
2.5 NMR Spectroscopy 
NMR spectra were recorded at room temperature (25 ± 1° C) in a Bruker Avance III 400 
spectrometer equipped with a Bruker Ultrashield 400 Plus superconducting magnet 
(resonating frequencies: 400.13, 100.61 MHz for 1H, 13C respectively) and a 5 mm 
PABBO BB-1H/D Z-GRD Z108618/0049 probe. 
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2.6 Raman spectroscopy  
Raman spectra were measured with a Bruker MultiRAM FT-Raman spectrometer, 
equipped with a Nd:YAG laser emitting at 1064 nm. The spectral resolution was 4 cm−1.  
 
2.7 Cellular studies (WST-1) 
Cells were seeded in a 96-well flat-bottomed plate (Corning-Costar, Corning, NY, USA); 
2×10 4 per well, 100 µL medium per well.  Experiments were carried out in the range 10-
150 µM (all experiments were performed in triplicate). After 24 h the medium was 
removed and replaced with fresh one containing the investigated compound at different 
concentrations. After further 24 h the medium was removed and wells added with 
medium containing 10 µL of WST-1 proliferation reagent. After 2 h of incubation, 
absorbance (proportional to the number of cells) was read at 450 nm to determine cells 
viability. 
  
6 
 
 
 
3. RESULTS AND DISCUSSION 
 
3.1 Synthesis and characterisation of tris-2,4,6-(2-pyrimidyl)-1,3,5-triazine (TpymT) 
and [Pt3(TPymT)(Cl)3]3+·3OH- 
Tris-2,4,6-(2-pyrimidyl)-1,3,5-triazine (TpymT) was synthetized modifying the 
procedure previously reported [11]. NH4Br (65 mg, 0.66 mmol) and 
diisopropylethylamine (DIPEA, 113 µl, 0.66 mmol) were added to a suspension of 2-
cyanopyrimidine (1.382 g, 13.2 mmol) in 1-pentanol (5 mL). The suspension was 
heated under stirring for 18 h in an oil bath kept at 135 °C. The reaction mixture was 
filtered and the solid extensively washed with acetonitrile. After washing, the pure 
product was obtained as a light brown solid in 73.5 % yield (1.015 g).  
The product was identified by comparing its 1HNMR spectrum [(DMSO-d6, 400.13 
MHz, 298K): 9.16 (d, 6H, J = 4.80 Hz); 7.82 (t, 3H, J = 4.84 Hz)] with the data 
reported in the literature [12] and further confirmation was obtained by recording 
1HNMR spectra of starting material (i.e. 2-pyrimidinecarbonitrile) and obtained 
product (i.e. TpymT) in D2O (see Supplementary Information). 
 
The trinuclear Pt2+ complex was prepared adding 140 mg (0.34 mmol) of K2PtCl4 to a 
suspension of 30 mg (0.097 mmol) of TPymT in ethanol (6 mL). The mixture was 
refluxed under stirring for 2 h; then, the solid precipitate was recovered in a Hirsch 
filter, washed with ultra-pure water and diethyl ether and dried under reduced 
pressure. The dark-brown product (78.1 mg; yield 85.9 %) was firstly characterized 
by elemental analysis for C15H12Cl3N9O3Pt3 [calculated C: 17.03%, H: 1.14%, N: 
11.92%; experimental: C: 16.97%, H: 1.11%, N: 11.63%], then with 1H and 13C 
NMR experiments performed in D2O and DMF-d7. 1HNMR (400.13MHz; DMF-d7): 
9.43 (2H; d; J = 5.28 Hz); 8.10 (1H; t; J = 5.28 Hz) (Figure 2), 13CNMR (100.61MHz; 
DMF-d7; DEPT-135 proton coupled): 156.96; 126.10.  
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<Figure 2 near here> 
 
The above characterisation was integrated with vibrational spectroscopy. Raman 
spectra of solid TpymT and of the synthesized complex were recorded, confirming 
the nature of the desired complex on the basis of the detection of a band at 341 cm-1, 
which can be assigned to a Pt-Cl stretching mode by comparison with literature 
spectra. Accordingly, the derived raw formula is [Pt3(TPymT)(Cl)3]3+·3OH- (see 
Supplementary Information for 1H NMR spectra in D2O, Raman spectra and details 
on Raman assignments).  
 
3.2 Solution Behaviour 
The solution behaviour of both L and Pt3L3+ under physiological-like conditions was 
investigated spectroscopically. A substantial stability in the buffer and upon light 
irradiation could be assessed as the respective UV-vis signatures and fluorescence 
emissions did not change noticeably within hours in PB buffer as well as in NaCac 
buffer (see Supporting Information). The ligand alone exhibits a maximum 
absorption at 249 nm, while the Pt(II) complex band shifts at the lowest limits of the 
acceptable window with a maximum at ca. 208 nm (Figure 3, ε249 = 3.79×104 M-1 cm-
1 and ε208 ≈ 5.2×105 M-1 cm-1 respectively). The direct proportionality between 
absorbance and concentration of the species is obeyed (in the explored range, i.e. 
below ca. 3×10-5M – not shown), suggesting the absence of auto-aggregation 
phenomena.  
< Figure 3 near here> 
 
3.3 DNA Interactions 
Afterward, the interactions with DNA of the Pt3L3+ complex and of the free ligand 
were comparatively analysed through a variety of methods to establish the strength of the 
occurring interactions and elucidate their nature.  
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3.3.1 Ethidium bromide displacement tests 
The absence of any significant UV-vis signal in a window out of that of the DNA, 
prevents direct spectrophotometric titrations (some tests confirmed the impossibility 
to deconvolute the contributions of the singles species in L/DNA or Pt3L3+/DNA 
spectrophotometric titrations). Therefore, an ethidium bromide (EB) fluorescent 
intercalator displacement assay [13, 14] was used to characterise the interactions with 
DNA. EB is known to be essentially non-fluorescent in buffer but highly emissive 
when intercalated into DNA (λmaxexc = 520 nm, λmaxem = 595 nm). Thus, DNA was 
first saturated with EB until maximum fluorescence was reached, then increasing 
amounts of the drug (L or Pt3L3+ - both non-fluorescent at λexc = 520 nm) were added 
to the mixture. Figure 4 shows the results obtained as F% = 100×F/F° (where F° is 
the read at zero addition and F is corrected for dilution effects) as a function of r = 
CD/CDNA. 
 
< Figure 4 near here> 
 
 
We observed that L is not able to produce significant changes in the fluorescence 
emission of EB/DNA, whereas Pt3L3+ addition causes a nearly complete fluorescence 
loss already at r = CD/CDNA = ca. 4. This fluorescence decrease can be explained on 
the basis of an interaction of the Pt3L3+ complex with DNA resulting into EB 
displacement from the polynucleotide base pairs. 
The exchange process can be expressed by the simplified model shown as reaction 
(1) [15].  
              Kex 
PEB + D ⇄ PD + EB 
          
(1) 
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where PEB is the EB/DNA adduct, D is the free Pt3L3+ complex, PD is the 
Pt3L3+/DNA adduct and EB is free ethidium. It should be noted that, under the 
applied experimental conditions (i.e. NaCl 0.1 M/NaCac 0.01 M, pH 7.0, 25° C), the 
binding constant for the formation of the EB/DNA complex is relatively high (KEB = 
2.6×105 M-1) [16]. The experimental results indicated that the exchange reaction is 
disfavoured in the case of L (too low Kex value). On the other hand, Kex can be 
calculated in the case of Pt3L3+ according to equation (2) (for its derivation, see 
Supporting Information) 
 
(CEB-	[PEB])

[PEB]
	Kex(CD − CEB + []) (2) 
where CD and CEB are the total analytical complex and ethidium concentrations 
respectively, whereas [PEB] is calculated as C°EB×F/F° (being PEB the only 
fluorescent species). It turns out (Figure 4 inset) that Kex = 0.11 ± 0.2 (total error over 
the triplicates). On this basis, the equilibrium constant for Pt3L3+ binding to DNA 
would be K = Kex × KEB ≈ 3×104 M-1. Note that this value should be intended as 
indicative, as based on a simplified model that considers a 1:1 stoichiometry for the 
exchange process.  
 
3.3.2 Melting tests 
Afterward, DNA melting tests were performed by measuring the absorbance changes 
of L/DNA or Pt3L3+/DNA mixtures at 260 nm [17] Figure 5A-B shows the results as 
%A = 100×(A-A°)/(A∞-A°) where A° is the absorbance plateau at low temperatures 
and A∞ is the absorbance plateau at high temperatures. Melting temperatures (Tm) are 
calculated as the inflection point of the sigmoid that fits the experimental data (Figure 
5C – overall error on the replicates). Pt3L3+ shows the strongest effects, with a 
destabilisation of the polynucleotide double helix that brings about a Tm decrease of 
about 4° C. 
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< Figure 5 near here> 
 
Melting temperature changes are not a direct measure of affinity but their extent 
allows to comment on the ability of the binding molecule to alter the stability of the 
double strand. In the case of intercalation of a small planar molecule between the 
base pairs a major stabilisation effect is observed (usually ∆Tm>10° C, [18]), 
whereas destabilisation can be related to groove binding) [19]. 
 
3.3.3 Viscometry 
Viscometric measurements were also carried out on both L/DNA and Pt3L3+/DNA 
mixtures at different reactants ratios (r = 0.25, 0.50, 0.75, 1.0, 2.0). Efflux times are 
treated to get the relative viscosity as η/η° = (t – tsolv)/(tDNA – tsolv) where tsolv and tDNA 
are the efflux times of buffer and DNA alone, respectively. Note that, as the ligand is 
insoluble in the buffer and should be solved in DMSO, small amounts of the latter 
solvent were present in the mixtures. As this can have a non-negligible effect on the 
efflux times, care was taken to keep the DMSO content constant (0.4 % v/v) in all 
L/DNA and Pt3L3+/DNA measurements. The cubic root of η/η° can be assumed as an 
evaluation of the elongation of the DNA strand; Figure 6 shows the results. Despite 
the relatively large errors inherent to the procedure, it can be clearly observed that 
both species do interact with DNA causing a compaction of the helix and that Pt3L3+ 
produces the strongest effects (ca. 20% compaction for Pt3L3+/DNA respect to 8% for 
L/DNA). This behaviour is in contrast with intercalation [20,21] and suggests 
bending of DNA driven by external binding [22,23]. 
 
< Figure 6 near here> 
 
Note that, in the case of the L/DNA system, the point at r = 2.0 seems to be slightly 
out of the trend, as confirmed by inspection of Figure 5C where the melting 
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temperature for r = 1.0 also suggests an upward trend. These data suggest some 
change in the binding effects in the presence of ligand excess, likely related to pi−pi 
dye-dye interactions on the DNA surface.  
 
 
3.3.4 Interaction with model oligonucleotide (ESI-MS) 
To shed further light on the occurring interactions we performed ESI-MS 
experiments after incubation of the study complex with a simple model of single 
strand DNA i.e. the dodecameric GG rich oligonucleotide CTACGGTTTCAC (ODN), 
according to the protocol developed in our laboratory [24-29]. In principle, by this 
approach, it is possible to describe the reaction pattern leading to metallodrug binding to 
the biomolecular model. Upon incubation of the study complex with the oligonucleotide 
at different complex to oligonucleotide ratios (i.e. 0.2:1 and 0.5:1), Pt3L3+ interacts with 
the model oligonucleotide only for the higher concentration of complex whereas no 
adduct formation was observed in the case of the lower concentration. The metalation 
process mainly occurs through preferential coordination of small hydroxylated 
monoplatinum fragments to ODN after Pt3L3+ complex disassembly and loss of the 
TPymT ligand, this representing the likely binding mechanism (see the ESI-MS spectrum 
in the Supplementary Information). The strong interaction occurring between platinum 
ions and purine nucleobases (given the known affinity of platinum drugs for N7 nitrogen 
of guanines [30]) might be the basis for the non-intercalative mode of binding of Pt3L3+. 
Moreover, the general geometry of this Pt complex is such that it can accommodate 
in the DNA grooves and achieve efficient interactions from the groove’s size. Also, 
the planar geometry of Pt3L3+ can drive some dye-dye pi−pi interactions on the DNA 
surface that would stabilise external binding. This effect has been already observed in 
the case of aromatic/hydrophobic dyes [31-33].  
 
3.3.5 Cellular effects 
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Next, the antiproliferative properties of the Pt3L3+ complex were measured in vitro 
against two cancer cell lines, HCT116 (colorectal, CRC) and MDA-MB-231 (breast).  
Pt3L3+ manifested IC50 values of 136.5±5.2 µM and 93.2±13.4 µM in HCT116 and 
MDA-MB-231 respectively; in both cases this value is significantly higher than that of 
cisplatin, having this latter an IC50 of about 25 µM for these two cell lines [34,35]. 
 
4. CONCLUSIONS 
In this study we have prepared and characterized, for the first time, the triplatinum 
complex of the TPymT ligand. The resulting complex is highly symmetric as clearly 
documented by the 1H NMR spectra. Notably, both the free ligand and its triplatinum 
complex turned out to be pretty stable under physiological-like conditions. Owing to 
its putative planar structure and to the presence of positive charges, we argued that 
Pt3L3+ might interact strongly with double helix DNA through intercalation. This 
prompted us to investigate its interactions with various DNA models through a 
variety of biophysical methods. Interactions with DNA were studied in comparison to 
the free ligand through ethidium bromide displacement, melting and viscometry 
assays.  
Remarkably, the triplatinum complex turned out to produce far more evident changes 
in the DNA structure than the free ligand. However, in contrast with expectations, our 
results strongly favour the occurrence of a non-intercalative binding mode. Indeed, an 
evident - though moderate - destabilization of the DNA double helix was observed in 
contrast to the usually large stabilization expected for intercalation. Also, no 
elongation (as it should occur for intercalation) but, instead, helix compaction was 
highlighted by viscometric tests. These results support the concept that the positively 
charged triplatinum complex interacts with the DNA molecules through 
external/groove binding interactions. Cellular experiments on two cell lines (HCT116 
and MDA-MB-231) were also carried out to assess the cytotoxic effect. The relatively 
high values of IC50 point out that Pt3L3+ is scarcely effective in these cancer cell lines 
again disfavouring the idea of intercalative DNA binding. By overall integration of 
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the obtained results, it may be hypothesised that the lack of intercalation leads to 
relatively poor pharmacological effects, being groove binding the main binding mode 
for the studied complex with double stranded DNA. This view is somehow supported 
by ESI-MS experiments indicating that, upon reaction with the single strand 
dodecameric oligonucleotide, Pt binding occurs through disassembly of the Pt3L3+ 
complex followed by coordination of small mono metallic fragments to the oligo. 
 
Supplementary Data 
NMR spectra of starting material for ligand synthesis, NMR of TpymT and PtL3+, 
ESI-MS spectrum of complex after incubation with oligonucleotide, Raman spectra for 
complex characterisation, UV-Vis for stability, derivation of equation (2). 
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Figure Captions 
 
Figure 1 – a) Chemical structures of the tris-2,4,6-(2-pyrimidyl)-1,3,5-triazine ligand 
(TPymT, L) and b) of its platinum complex ([(TPymT)Pt3(Cl)3]3+, Pt3L3+). 
Figure 2 –1HNMR Spectrum of Pt3L3+ recorded at 298K, DMF-d7 (400.13 MHz): δ 
9.43 (2H, d; J = 5.28 Hz); δ 8.10 (1H, t; J = 5.28 Hz). 
Figure 3 – Absorbance spectra of L (straight, left y-axis) and Pt3L3+ (dotted, right y-
axis and inset); [NaCl] = 0.1 M, [NaCac] = 0.01 M, pH 7.0, 25.0 °C. 
 
Figure 4. Example of EB/DNA exchange tests using L (●) or Pt3L3+ (■); CDNA = 
1.55×10-4 M, CEB = 5.9×10-5 M, r = CD/CDNA, NaCl 0.1 M/NaCac 0.01 M, pH 7.0, λexc 
= 520 nm, λem = 595 nm, 25.0 °C. In the inset, x = CD – CEB + [EB/DNA], y = (CEB - 
[EB/DNA])2/[EB/DNA] with [EB/DNA] = C°EB×F/F° and the continuous line is data 
fit according to equation (2). 
 
Figure 5. Melting tests on the L/DNA (A) and Pt3L3+/DNA (B) systems at different 
values of r = CD/CDNA;  CDNA = 2.50×10-5 M, pH 7.0, λ = 260 nm, NaCl 0.1 M/NaCac 
0.01 M. (C) Melting temperatures as a function of r for L/DNA (●) and Pt3L3+/DNA 
(■) systems.   
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Figure 6. Relative viscosity of L/DNA (●) and Pt3L3+/DNA (■) systems at different 
values of r = CD/CDNA; CDNA = 2.0×10-4 M, pH 7.0, NaCl 0.1 M/NaCac 0.01 M, 25.0 
°C.  
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